Chapters on pigment loss, stress signalling, follicle failure, and the evidence that still leaves room for intervention.
Open the Journal →Hair Labs · Research · Batch 001
Anti Grey 1.0 is written for that window: six greying drivers, pairwise-modelled into one two-capsule protocol and reviewed before release.
In brief.
Grey hair is not one deficiency. It is a six-driver failure at the follicle. Anti Grey 1.0 is the first protocol to leave the Hair Labs greying model: the five-compound NooPigment Matrix™, the Co-Factor Circuit around it, and pairwise modelling across the finished two-capsule protocol.
Greying is not one failure. Six biological drivers converge on a single outcome — the pigment cell stops arriving at the follicle. The ledger below keeps the diagnosis and modelled response together before the field comparison and formulation.
The pigment reserve can become stranded in the upper bulge. Sun 2023. Endothelin-1 / Ednrb signalling then fails, and the follicle stops recruiting colour. Iida 2024. The older foundation is incomplete melanocyte stem-cell maintenance in the niche. Nishimura 2005.
Response · · 100 mg · from Sophora japonica flower bud · standardised to ≥98%.
Noradrenaline released by sympathetic nerves can empty the pigment reserve in mice. Human single-hair mapping links stress load and reversal under threshold conditions. Zhang 2020; Rosenberg 2021.
Response · · 300 mg · standardised withanolides · · 100 mg · standardised rosavins and salidroside.
Melanin synthesis needs l-tyrosine as substrate and copper-bound tyrosinase as the rate-limiting enzyme. Slominski 2012.
Response · · 500 mg · · 1.5 mg · as gluconate.
The one-carbon cycle supplies methyl groups pigment-cell function relies on. Deficiency signals around Colecalciferol, Cobalamin, Folate, and lower-normal Biotin are reported in premature-canities cohorts; this is support biology, not a reversal claim. Bhat 2013; Daulatabad 2017.
Response · · 100 µg · · 400 µg · · 10 mg · · 100 mg · · 50 mg · · 25 µg.
The shaft has to hold the colour the follicle lays down. Biotin and pantothenic acid support the keratin and energy lane behind tensile strength.
Response · · 5 mg.
Hydrogen peroxide accumulates as catalase activity declines; the redox environment oxidises melanogenic enzymes and shaft structure. Wood 2009; Trüeb 2009.
Response · · 100 mg.
Most approaches to greying address one driver, sometimes two. Anti Grey 1.0 is written against the full six-driver map: signalling, stress load, substrate supply, methylation, fibre structure, and oxidative pressure, then checked by pairwise modelling before release.
A formulation is not the sum of its compounds; it is the sum of which drivers they cover together, at dose. Anti Grey 1.0 is the modelled answer: Matrix, Circuit, and pairwise constraints mapped back to the six-driver field.
The NooPigment Matrix™ is the five-compound answer at the centre of the model. The Co-Factor Circuit sits around it: eight supporting compounds that keep the Matrix usable inside one two-capsule protocol. Together they answer signalling, stress load, substrate supply, methylation, fibre structure, and oxidative pressure.
Dose, form, driver code, and monograph route.
Preserves endothelin signalling between keratinocyte and melanocyte stem cells; suppresses senescent p16ink4a+ stem-cell accumulation in the bulge; attenuates peroxide-type oxidative stress at the follicle.
Iida et al., 2024.
The biological substrate of melanogenesis — fed into tyrosinase-driven pigment synthesis. Coupled to Copper (Circuit) as its catalytic cofactor.
Slominski et al., 2012.
HPA-axis modulation; the slower arm of the stress lane. Sustains the biochemical stage on which the pigment lane can run.
Chandrasekhar et al., 2012.
Sympathetic-nerve buffering — the acute-stress arm, mapped to the Zhang 2020 axis where noradrenaline empties the pigment reserve in a single shot.
Darbinyan et al., 2007.
Methyl-group donor via betaine; the bridge between the stress lane and the methylation lane the Circuit carries. Included as the active methylation support, not as a standalone greying claim.
One-carbon-cycle formulation rationale.
The Matrix is not the protocol on its own. The Circuit keeps each Matrix compound inside range and carries substrate, methylation, redox, and structural support.
The dependency layer, mapped to the same six-driver field.
Regenerates Luteolin at its reversible redox intermediates — the coupling worked in full as FIG. 04.
Tyrosinase's catalytic cofactor — L-Tyrosine does nothing pigment-wise without it. As gluconate; form chosen to coexist with the vitamin complex.
Initiates methionine synthase and homocysteine recycling. The cobalt-centred vitamer at the top of the one-carbon cycle.
Bio-ready methyl donor for the remethylation step. Form selected to work across common MTHFR genotypes.
Closes the homocysteine loop via trans-sulphuration. Also activates melanogenic enzymes on the pigment lane.
Keratin-carboxylase cofactor — carries driver 05 (structural integrity) on its own; a healthy scaffold for new colour to land on.
Coenzyme A — the energy lane that keratin synthesis runs on. Paired with Biotin across the structural driver.
Endocrine support of the methylation and structural lanes. The widely-deficient modern vitamer kept at physiological maintenance dose.
The Matrix and Circuit are the formulation architecture. Pairwise modelling is the apparatus that tests whether that architecture can hold together as one protocol. The next chapter — § 04 — shows the constraint test.
Pairwise modelling is the in silico apparatus behind the greying protocol. FIG. 03 publishes the NooPigment Matrix™: five compounds, ten Matrix × Matrix checks, five constraints per pair. The same constraint model is then run across the Co-Factor Circuit, producing seventy-eight pair checks across the finished two-capsule protocol. FIG. 04 works one dependency — Luteolin × Ascorbic Acid — in full.
10 / 10 Matrix pairs · constraint-scored
The ten Matrix pairs above are the visible apparatus. The same in silico constraint model is run across the Co-Factor Circuit before the two-capsule protocol is locked.
The pair checks are not abstract. They return to the greying map: six biological drivers, one finished protocol.
Luteolin carries the signalling answer; Ascorbic Acid protects the reversible redox window around it.
Ashwagandha and Rhodiola split the stress lane: baseline HPA-axis load and acute sympathetic stress.
L-Tyrosine supplies the melanin precursor; Copper supplies the tyrosinase cofactor.
Choline, Cobalamin, Folate, Pyridoxine, and Colecalciferol support the one-carbon and metabolic lane.
Biotin, Pantothenic Acid, and Colecalciferol support the structural environment in which new hair is built.
Luteolin, Ascorbic Acid, and Pyridoxine support the redox lane; Luteolin × Ascorbic Acid is worked in FIG. 04.
Luteolin × Ascorbic Acid is the first Matrix × Circuit dependency — the coupling the formulation load-bears on, shown here in full. It is the pair a sceptical reader can check in thermodynamic detail.
Ascorbate sits below Luteolin in the antioxidant pecking order — a competent electron donor to both intermediates. The amber return path is the regeneration: every −e⁻ oxidation step has a paired +ascorbate reduction step, so Luteolin re-enters the reduced state at both stages.
Luteolin's catechol B-ring (the 3′,4′-dihydroxy ring) undergoes reversible one-electron oxidation to a phenoxyl / semiquinone radical, and by a second oxidation to the o-quinone. Both intermediates are reversible. The one-electron redox potential of Luteolin•/Luteolin sits at ~ +600 mV at pH 7; Ascorbate's couple at ≈ +282 mV. Ascorbate therefore sits below Luteolin in the antioxidant pecking order and is a competent electron donor to both intermediates — regenerating reduced Luteolin for the next redox turn. The ascorbyl radical produced either disproportionates or is reduced back to ascorbate by cellular reductase systems.
Scope of the claim.
The regeneration cycle holds for the reversible intermediates. Luteolin consumed by nucleophilic adduct formation (e.g. with GSH or protein Cys residues), by radical–radical coupling, or by ring-opening / hydrolytic degradation, exits the pool and is not recoverable by ascorbate. The cycle sustains across the reversible window; the fraction of Luteolin that stays inside that window depends on local thiol tone, radical flux, and formulation physics — not on dose alone.
Iida et al, 2024 · Wölfle et al, 2011 · Buettner, 1993 · Jovanovic et al, 1994.
Research updates.
Batch 002 readout is expected Q3 2026. We send Research updates when the record changes.
The formulation problem is not find an ingredient that helps. Given six greying drivers and a realistic two-capsule dose envelope, the question is: which compounds, at which doses, at which forms, answer each driver without compromising another? Computation is how Hair Labs held more than six hundred candidates comparable on the same terms.
The literature supplies the mechanisms. In silico pairwise modelling supplies the constraint filter. The Clinical Advisory Board analyses the protocol before release. The computation's work is the apparatus — deciding which compounds survive the five constraints when put against every other.
Structured literature mapping turns twenty years of papers on melanocyte stem-cell biology, the methylation cycle, trichology, and follicular oxidative chemistry into a corpus indexed by mechanism, not by compound. Candidate compounds are then judged against the driver they act on.
Candidate compounds are enumerated as pairs and scored on five constraints (see FIG. 03): redox compatibility, cofactor dependency, methylation-lane fit, absorption and form, and two-capsule discipline. Pharmacology at this breadth is tractable by a model, not by hand.
Each pair is evaluated against standard pharmacological interaction models — Bliss independence for probabilistic effects, Loewe additivity for dose-equivalent effects. These are guardrails: they keep possible synergy, additivity, and antagonism explicit in the score rather than assumed. This is where a claim like Luteolin × Ascorbic Acid has to land on real thermodynamics or be retired.
Pairs that fail any constraint are dropped or re-formed. Ascorbic Acid's form is chosen to regenerate Luteolin's oxidised intermediates rather than compete with them; copper is dosed as gluconate to coexist with the vitamin complex without displacing zinc absorption; choline is preferred over higher-dose betaine to stay inside the two-capsule envelope.
The remainder — five Matrix compounds and eight Circuit compounds across the six systems, each at scored dose and form — goes to the Clinical Advisory Board before Batch 001 is released.
More than six hundred candidates reduced to one greying protocol — five Matrix compounds and eight Circuit compounds that hold the pairwise constraints at scored dose and form.
Every accepted compound is the product of rejecting many others. The exclusions carry as much information as the inclusions — they document the discipline the formulation is written under. Four rejections stand for the set.
Fo-Ti (Polygonum multiflorum).
Rejected — hepatotoxicity signal in the clinical literature.
Raw and processed Fo-Ti root preparations are documented causes of drug-induced liver injury in the published clinical literature. WHO pharmacovigilance reviews and repeated case series report hepatotoxicity presenting as cholestatic or mixed injury; the UK MHRA has historically issued safety warnings on products containing the herb. Hair Labs does not formulate against a target that carries a live hepatic safety signal.
PABA (para-aminobenzoic acid).
Rejected — flagged for safety concerns at the doses historically used.
Positioned historically as a pigmentation supplement following mid-twentieth-century case reports. Regulatory scrutiny (Health Canada, EFSA) has flagged safety concerns at the doses historically used, including rare but reported hepatitis. The formulation does not rely on this category.
Oral catalase.
Rejected — pharmacokinetically incapable of acting where it would need to.
Catalase is the enzyme that clears hydrogen peroxide in the follicle; the deficit is local. Oral catalase is a protein and is proteolysed in the gastrointestinal tract before it reaches the follicle — it cannot act at the site. The correct intervention on this driver is upstream: reducing the peroxide load and supporting the redox chemistry that preserves endogenous catalase activity. That is how Anti Grey 1.0 is constructed.
Stack more ingredients.
Rejected — dose compression dilutes every compound below scored effect.
The commercial convention in the category is twenty or thirty actives in an undisclosed blend. Dose compression dilutes each compound below the threshold at which the published literature reports an effect, and no single driver is answered at scored dose. The formulation discipline here is the opposite: fewer compounds, each at the dose the literature scored, packed into an envelope small enough to survive daily adherence.
A formulation is the sum of its rejections.
Batch 001 is an observed respondent corpus, not a clinical endpoint. It sits here as an early field signal after the mechanism, formulation, computation, and rejection ledger.
Batch 001 respondents on oral Anti Grey 1.0.
60 respondents answered the standardised question set. The wider 127 review count is separate and never used as an outcome denominator.
Months 3–6 on protocol, when new growth can begin to show whether fewer new greys are forming.
Respondent corpus · standardised question set · oral protocol only.
Field signal only. The literature, six-driver model, formulation architecture, and pairwise apparatus carry the primary proof burden.
The four percentages are the four outcomes asked in the standardised question set. Hair Labs publishes the smaller strength figure alongside the larger pigment, density, and shedding signals because no outcome is withheld.
Respondent-reported outcomes are not clinical endpoints. The standardised question set is available on request.
Hair Labs works with clinicians, trichologists, doctors, and pharmacist-manufacturing partners across the biology of hair ageing. Anti Grey 1.0 is the first protocol to pass through that advisory system.
Clinical Advisory Board · 01
Consultant Trichologist · IAT · IOT
London, United Kingdom. Practices in New York.
Analysed the formula from a clinical trichology perspective and advised on how the protocol should read against real presentations of ageing hair, pigment change, scalp health, and hair quality.
Clinical Advisory Board · 02
Board-certified Trichologist · MIT · AIT · PsyD
London, United Kingdom.
Reviewed the pigment-biology and trichology framing of the protocol.
Clinical Advisory Board · 03
Nutrition scientist · PhD, Imperial College London
Oxford, United Kingdom.
Reviewed the stress physiology, adaptogen, and nutrition-science context around maintaining hair pigmentation over time.
Education Faculty · Melanocyte biology
Aesthetics Doctor / GP · MBBS, Imperial College London
Cambridge and Hertfordshire, United Kingdom.
Journal field: melanocyte stem-cell reserve and pigment biology.
Education Faculty · Systems biology
Family physician · Aesthetic medicine · University of Toronto adjunct lecturer
Toronto, Canada.
Journal field: systems biology, oxidative stress, and follicular signalling.
Education Faculty · Clinical trichology
Trichologist · IAT-trained · 20 years in hair and scalp practice
United Kingdom.
Journal field: clinical trichology and multifactorial follicle health.
The full Clinical Advisory Board page carries CAB member detail, Education Faculty, protocol context, and manufacturing standards.
Primary literature cited in this document.
(2005). Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science.Read ↗
(2020). Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature.Read ↗
(2021). Quantitative mapping of human hair greying and reversal in relation to life stress. eLife.Read ↗
(2023). Dedifferentiation maintains melanocyte stem cells in a dynamic niche. Nature.Read ↗
(2024). Anti-Graying Effects of External and Internal Treatments with Luteolin on Hair in Model Mice. Antioxidants.Read ↗
(2012). L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell & Melanoma Research.Read ↗
(2012). A prospective, randomized double-blind, placebo-controlled study of the safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine.Read ↗
(2007). Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic Journal of Psychiatry.Read ↗
(2013). Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. International Journal of Trichology.Read ↗
(2017). Prospective analytical controlled study evaluating serum biotin, vitamin B12, and folic acid in patients with premature canities. International Journal of Trichology.Read ↗
(2011). UVB-induced DNA damage, generation of reactive oxygen species, and inflammation are effectively attenuated by the flavonoid Luteolin in vitro and in vivo. Free Radical Biology and Medicine.Read ↗
(2009). Senile hair graying: H₂O₂-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB Journal.Read ↗
(2009). Oxidative stress in ageing of hair. International Journal of Trichology.Read ↗
(1993). The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate. Archives of Biochemistry and Biophysics.Read ↗
(1994). Flavonoids as antioxidants. Journal of the American Chemical Society.Read ↗
Method, denominator, computation, and claim boundary — the parts a sceptical reader should be able to check.
Hair grows approximately one centimetre per month. A follicle-root protocol reads through newly formed hair, not the shaft already visible.
Quality, texture, strength, and shedding can move first. Pigment biology is slower because fewer new greys can only be judged through new growth, which is why Batch 001 is reported at months 3–6.
The outcome percentages use only the respondents who answered the standardised Batch 001 question set. The wider product review count is separate and is not used to calculate those percentages.
The chart publishes every outcome asked in that corpus: less new grey, fuller or thicker hair, less shedding, and stronger strands.
Anti Grey 1.0 is not built as a category stack. It is written to the six-driver map of greying, then constrained by dose, form, pair compatibility, and the two-capsule envelope.
The NooPigment Matrix (§ 03), pairwise apparatus (FIG. 03), Luteolin × Ascorbic Acid worked example (FIG. 04), rejections ledger (§ 06), and contributor review (§ 07) are the difference.
Anti Grey 1.0 is written by people. Pairwise modelling holds the bookkeeping: more than six hundred candidates upstream, then seventy-eight compound pairs across the finished Matrix and Circuit.
The computation does not write claims, replace contributor review, or substitute for the literature under each compound. It keeps the constraint problem checkable.
Prevention is the claim. Anti Grey 1.0 is written to reduce new greying by supporting the six systems pigment biology depends on.
Reversibility remains biologically serious: Rosenberg et al., 2021 documented natural repigmentation along individual human hair shafts. That observation belongs in the science. It is not a product promise.
Anti Grey 1.0 is formulated and compounded by registered UK pharmacists in Kensington, London. Batch 001 first entered protocol use in September 2025; the month 3–6 respondent corpus was collected after that first use window.
US fulfilment opened after the first readout. The full ingredient panel, excipients, and practical protocol notes live on the product page.
